Results 81 to 90 of about 2,648 (201)
Plain Language Summary: What is this summary about? X-linked hypophosphatemia (XLH for short) is a rare genetic condition in which people have low levels of phosphate in their blood.
Levtchenko E. +35 more
core +1 more source
In recent years, much progress has been made in understanding the mechanisms of bone growth and development over a lifespan, including the crosstalk between muscle and bone, to achieve optimal structure and function.
Harvey, Nicholas +6 more
core +1 more source
Dental Management of Children with X-Linked Hypophosphatemia (XLH): A scoping review and exploration of patient-reported outcome measure (PROM) [PDF]
Introduction: X-Linked Hypophosphatemia (XLH) is a genetic multisystem disorder, characterised by low levels of phosphate in the blood causing distinctive skeletal and dental manifestations.// Aims and objectives: The aim was to review medical and ...
Al-Otaibi, Basmah
core +1 more source
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
Sclerostin emerges as a novel target for bone anabolic therapy in bone diseases. Osteogenesis imperfecta (OI) and X-linked hypophosphatemia (XLH) are rare bone diseases in which therapeutic potential of sclerostin inhibition cannot be ignored.
Tao Xiaohui +22 more
doaj +1 more source
A: SIBLING proteins containing the ASARM peptide are processed by a multitude of proteolytic enzymes, some of which may release the ASARM peptide or larger protein fragments containing the ASARM peptide into the extracellular matrix (ECM).
Eric Huet (381328) +17 more
core +1 more source
SUN-757 Sustained Improvements in Patient-Reported Outcomes Across Age Groups in Burosumab-Treated X-linked Hypophosphatemia (XLH): Results From the XLH Disease Monitoring Program [PDF]
Introduction: Burosumab, a fully human FGF23-neutralizing antibody, improved outcomes in adults and children with X-linked hypophosphatemia (XLH) in 24- and 64-week randomized controlled trials, respectively. This analysis describes real-world changes in
Li, Jerry +10 more
core +1 more source
Hypophosphatemia presents with highly variable clinical manifestations. Among the identified hypophosphatemic disorders, X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) are caused by persistent excess fibroblast growth factor 23 ...
Maria Luisa Brandi +6 more
doaj +1 more source
Evaluation of dental manifestations in X-linked hypophosphatemia using orthopantomography.
BackgroundX-linked hypophosphatemia (XLH) is the most common inherited form of rickets. The presence of sequence variations in the phosphate regulating endopeptidase homolog X-linked (PHEX) gene is associated with increased production of fibroblast ...
Rena Okawa +4 more
doaj +1 more source
The Role of GDF5 in Regulating Enthesopathy Development in the Hyp Mouse Model of XLH
X-linked hypophosphatemia (XLH) is caused by mutations in PHEX, leading to rickets and osteomalacia. Adults affected with XLH develop a mineralization of the bone-tendon attachment site (enthesis), called enthesopathy, which causes significant pain and ...
Alayyat, Ahmad +9 more
core +1 more source

